^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PIK3CA mutation + HRAS mutation

    i
    Other names: PIK3CA, Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, Phosphoinositide-3-kinase, catalytic, alpha polypeptide, Serine/threonine protein kinase PIK3CA, PtdIns-3-kinase subunit P110-alpha, PI3K-alpha, Phosphatidylinositol-4,5-bisphosphate 3-kinase 110 KDa catalytic subunit alpha, Phosphatidylinositol 3-kinase, Catalytic, 110-KD, alpha, PI3-kinase P110 subunit alpha, PI3-kinase subunit alpha, PtdIns-3-kinase subunit alpha, PI3Kalpha, P110alpha, PI3K, HRAS, HRAS1, Harvey ra
    Entrez ID:
    5290; 3265
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    over3years
    Clinicopathological study of intraductal carcinoma of the salivary gland, with emphasis on the apocrine type. (PubMed, Virchows Arch)
    The monoclonal antibody (clone RBT-NRAS) against NRAS Q61R is a sensitive and specific marker used for detecting HRAS Q61R mutation in the salivary gland tumors. The apocrine-type IC had different cytological grades, distinct tumor growth patterns, and no evidence of low- to high-grade transition, suggesting that apocrine-type IC should be distinguished from apocrine SDC with an in situ component.
    Clinical • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog) • SOX10 (SRY-Box 10)
    |
    HER-2 amplification • PIK3CA mutation • RET fusion • RET mutation • PIK3CA amplification • HRAS mutation • RET rearrangement • NRAS Q61 • NRAS Q61R • HRAS Q61R • PIK3CA mutation + HRAS mutation
    over3years
    Assessment of prognostic implication of a panel of oncogenes in bladder cancer and identification of a 3-gene signature associated with recurrence and progression risk in non-muscle-invasive bladder cancer. (PubMed, Sci Rep)
    Genomic alterations in MIBC revealed in TCGA data also concern NMIBC and seem to be associated with prognosis in terms of recurrence and progression. Correcting these alterations by targeted therapies seems a promising pharmacological approach.
    Journal • Gene Signature
    |
    EGFR (Epidermal growth factor receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FGFR3 (Fibroblast growth factor receptor 3) • HRAS (Harvey rat sarcoma viral oncogene homolog) • TERT (Telomerase Reverse Transcriptase) • ERCC2 (Excision repair cross-complementation group 2)
    |
    PIK3CA mutation • EGFR overexpression • FGFR3 mutation • FGFR3 overexpression • HRAS mutation • PIK3CA mutation + HRAS mutation
    over3years
    [VIRTUAL] Targeted next-generation sequencing of circulating tumor DNA identifies mutations in ESR1 and TP53 as the main predictors of progression-free and overall survival in patients with metastatic estrogen receptor-positive, HER2-negative breast cancer (DGHO 2020)
    Mutations in ESR1 and TP53 are the main predictors of progression free and overall survival in oestrogen receptor-positive, HER2-negative MBC patients.
    Clinical • Next-generation sequencing
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • PTEN (Phosphatase and tensin homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    TP53 mutation • KRAS mutation • ER positive • HER-2 negative • PIK3CA mutation • PTEN mutation • ER mutation • HRAS mutation • PIK3CA mutation + ER positive • AR mutation • ER positive + HER-2 negative • PIK3CA mutation + HRAS mutation • PIK3CA mutation + PTEN mutation + KRAS mutation
    over3years
    [VIRTUAL] Targeted next-generation sequencing of circulating tumor DNA identifies mutations in ESR1 and TP53 as the main predictors of progression-free and overall survival in patients with metastatic estrogen receptor-positive, HER2-negative breast cancer (DGHO 2020)
    Mutations in ESR1 and TP53 are the main predictors of progression free and overall survival in oestrogen receptor-positive, HER2-negative MBC patients.
    Clinical • Next-generation sequencing
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • PTEN (Phosphatase and tensin homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    TP53 mutation • KRAS mutation • ER positive • HER-2 negative • PIK3CA mutation • PTEN mutation • ER mutation • HRAS mutation • PIK3CA mutation + ER positive • AR mutation • ER positive + HER-2 negative • PIK3CA mutation + HRAS mutation • PIK3CA mutation + PTEN mutation + KRAS mutation
    over3years
    [VIRTUAL] Targeted next-generation sequencing of circulating tumor DNA identifies mutations in ESR1 and TP53 as the main predictors of progression-free and overall survival in patients with metastatic estrogen receptor-positive, HER2-negative breast cancer (DGHO 2020)
    Mutations in ESR1 and TP53 are the main predictors of progression free and overall survival in oestrogen receptor-positive, HER2-negative MBC patients.
    Clinical • Next-generation sequencing
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • PTEN (Phosphatase and tensin homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    TP53 mutation • KRAS mutation • ER positive • HER-2 negative • PIK3CA mutation • PTEN mutation • ER mutation • HRAS mutation • PIK3CA mutation + ER positive • AR mutation • ER positive + HER-2 negative • PIK3CA mutation + HRAS mutation • PIK3CA mutation + PTEN mutation + KRAS mutation
    over3years
    [VIRTUAL] Targeted next-generation sequencing of circulating tumor DNA identifies mutations in ESR1 and TP53 as the main predictors of progression-free and overall survival in patients with metastatic estrogen receptor-positive, HER2-negative breast cancer (DGHO 2020)
    Mutations in ESR1 and TP53 are the main predictors of progression free and overall survival in oestrogen receptor-positive, HER2-negative MBC patients.
    Clinical • Next-generation sequencing
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • PTEN (Phosphatase and tensin homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    TP53 mutation • KRAS mutation • ER positive • HER-2 negative • PIK3CA mutation • PTEN mutation • ER mutation • HRAS mutation • PIK3CA mutation + ER positive • AR mutation • ER positive + HER-2 negative • PIK3CA mutation + HRAS mutation • PIK3CA mutation + PTEN mutation + KRAS mutation
    over3years
    Pulmonary epithelial-myoepithelial carcinoma without AKT1, HRAS or PIK3CA mutations: a case report. (PubMed, Diagn Pathol)
    Pulmonary epithelial-myoepithelial carcinoma is a rare subtype of lung cancer, with only 56 previous cases reported in the English literature. The genetic alterations in pulmonary epithelial-myoepithelial carcinoma are still unknown. We examined the 6 genes mutation analysis, however no mutation was detected.
    Clinical • Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • HRAS (Harvey rat sarcoma viral oncogene homolog) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1)
    |
    KRAS mutation • BRAF mutation • PIK3CA mutation • HRAS mutation • AKT1 mutation • PIK3CA mutation + HRAS mutation
    over3years
    Clinicopathological and Molecular Differences Between Gastric-type Mucinous Carcinoma and Usual-type Endocervical Adenocarcinoma of the Uterine Cervix. (PubMed, Cancer Genomics Proteomics)
    GMC is associated with more aggressive behavior than UEA. Distinctive p53 and p16 immunostaining patterns enable differential diagnosis. GMC and UEA exhibit genetic heterogeneity with potentially actionable molecular alterations.
    Clinical • Journal • BRCA Biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BRCA2 (Breast cancer 2, early onset) • STK11 (Serine/threonine kinase 11) • HRAS (Harvey rat sarcoma viral oncogene homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ARID1A (AT-rich interaction domain 1A) • MDM2 (E3 ubiquitin protein ligase)
    |
    TP53 mutation • KRAS mutation • BRCA2 mutation • PIK3CA mutation • ARID1A mutation • STK11 mutation • NF1 mutation • MDM2 amplification • PIK3CA amplification • HRAS mutation • KRAS mutation + STK11 mutation • PIK3CA mutation + HRAS mutation
    over3years
    miRNA expression can classify pediatric thyroid lesions and increases the diagnostic yield of mutation testing. (PubMed, Pediatr Blood Cancer)
    These data suggest that the regulatory miRNA pathways underlying thyroid tumorigenesis are similar in adults and children. miRNA expression can identify malignant lesions with high specificity, augment the diagnostic yield of mutation testing, and improve the molecular classification of pediatric thyroid nodules.
    Clinical • Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • HRAS (Harvey rat sarcoma viral oncogene homolog) • PPARG (Peroxisome Proliferator Activated Receptor Gamma)
    |
    KRAS mutation • BRAF mutation • NRAS mutation • PIK3CA mutation • ALK positive • ALK rearrangement • HRAS mutation • PIK3CA mutation + HRAS mutation
    almost4years
    Relevance and actionable mutational spectrum in oral squamous cell carcinoma. (PubMed, J Oral Pathol Med)
    Data generated from our study may enable an application of targeted NGS analysis of driver mutations for better therapeutic choice and improved outcomes for OSCC subjects when combined with clinical diagnosis.
    Journal
    |
    TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • ATM (ATM serine/threonine kinase) • HRAS (Harvey rat sarcoma viral oncogene homolog) • SMAD4 (SMAD family member 4) • ERBB4 (erb-b2 receptor tyrosine kinase 4)
    |
    TP53 mutation • PIK3CA mutation • ATM mutation • HRAS mutation • PIK3CA mutation + HRAS mutation
    almost4years
    Mutation analysis and genomic imbalances of cells found in effusion fluids from patients with ovarian cancer. (PubMed, Oncol Lett)
    The molecular profiling of cells found in effusion fluids from patients with ovarian cancer thus showed considerable molecular heterogeneity. TP53 seems to be the most frequently mutated gene in these cells and may serve a leading role in the metastatic process.
    Clinical • Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    TP53 mutation • KRAS mutation • BRAF mutation • NRAS mutation • PIK3CA mutation • HRAS mutation • PIK3CA mutation + HRAS mutation
    almost4years
    Recurrent genetic alterations and biomarker expression in primary and metastatic squamous cell carcinomas of the vulva. (PubMed, Hum Pathol)
    Our results further confirmed the genetic alterations that are amenable to targeted therapy, offering the potential for individualized management strategies for the treatment of these aggressive tumors with different etiology. Discordant PD-L1 expression in the primary and metastatic vulvar SCCs highlights the importance of evaluation of PD-L1 expression in different locations to avoid false negative information provided for immunotherapy.
    Journal • BRCA Biomarker • PD(L)-1 Biomarker
    |
    PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NOTCH1 (Notch 1) • KDR (Kinase insert domain receptor) • BAP1 (BRCA1 Associated Protein 1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • BIRC3 (Baculoviral IAP repeat containing 3)
    |
    PD-L1 expression • TP53 mutation • BRCA2 mutation • PIK3CA mutation • PTEN mutation • NOTCH1 mutation • CDKN2A mutation • BAP1 mutation • PIK3CA amplification • HRAS mutation • PIK3CA mutation + HRAS mutation
    4years
    [VIRTUAL] Exploring possible drug resistance and sensitivity mechanisms in treatment-refracotry betel-nuts related HNSCC cell line(TW2.6) by whole exon sequencing and molecular signaling for future drug combinations (AACR-II 2020)
    TW2.6 had PIK3CA H1047R mutation, high TMB(8.42 muts/Mb)/MSS, and VEGF-A amplification. We found afatinib response on several cell lines not so correlated to EGFR expression & CNV status. Palbociclib response seemed to correlate to CCND1 gain and p16 loss; but FaDu had not so good palbociclib response even with these two changes and TW2.6 has good response even without these two.
    Preclinical • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MET (MET proto-oncogene, receptor tyrosine kinase) • STK11 (Serine/threonine kinase 11) • HRAS (Harvey rat sarcoma viral oncogene homolog) • AXL (AXL Receptor Tyrosine Kinase) • CCND1 (Cyclin D1) • FAT1 (FAT atypical cadherin 1) • ATR (Ataxia telangiectasia and Rad3-related protein) • SOX9 (SRY-Box Transcription Factor 9) • DDR2 (Discoidin domain receptor 2) • FGF10 (Fibroblast Growth Factor 10)
    |
    TP53 mutation • PIK3CA mutation • EGFR expression • PIK3CA H1047R • STK11 mutation • BCL2 overexpression • PIK3CA amplification • HRAS mutation • FGF10 amplification • PIK3CA mutation + HRAS mutation
    |
    Gilotrif (afatinib) • Ibrance (palbociclib)
    4years
    [VIRTUAL] Characterization of BRAF mutation in Chinese colorectal cancer patients using next generation sequencing (AACR-II 2020)
    In our study, the mutation type, frequency, classification of BRAF mutations and co-occurrence with BRAF and other driver gene mutations were explored in a large cohort of Chinese colorectal cancer patients, which might help to suggest proper therapy methods.
    Clinical • Next-generation sequencing
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • PTEN (Phosphatase and tensin homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    BRAF V600E • BRAF mutation • PIK3CA mutation • BRAF V600 • PTEN mutation • HRAS mutation • MTOR mutation • PIK3CA mutation + HRAS mutation